GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (TSE:4568) » Definitions » Cash Flow from Financing

Daiichinkyo Co (TSE:4568) Cash Flow from Financing : 円-123,564 Mil (TTM As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, Daiichinkyo Co paid 円8 Mil more to buy back shares than it received from issuing new shares. It received 円385 Mil from issuing more debt. It paid 円0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received 円61 Mil from paying cash dividends to shareholders. It received 円0 Mil on other financial activities. In all, Daiichinkyo Co earned 円438 Mil on financial activities for the three months ended in Mar. 2024.


Daiichinkyo Co Cash Flow from Financing Historical Data

The historical data trend for Daiichinkyo Co's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Cash Flow from Financing Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -91,637.00 -202,433.00 -86,231.00 -89,594.00 -123,564.00

Daiichinkyo Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,792.00 -32,528.00 -44,751.00 -42,446.00 -3,839.00

Daiichinkyo Co Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Daiichinkyo Co's Cash from Financing for the fiscal year that ended in Mar. 2024 is calculated as:

Daiichinkyo Co's Cash from Financing for the quarter that ended in Mar. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-123,564 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daiichinkyo Co  (TSE:4568) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Daiichinkyo Co's issuance of stock for the three months ended in Mar. 2024 was 円0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Daiichinkyo Co's repurchase of stock for the three months ended in Mar. 2024 was 円-8 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Daiichinkyo Co's net issuance of debt for the three months ended in Mar. 2024 was 円385 Mil. Daiichinkyo Co received 円385 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Daiichinkyo Co's net issuance of preferred for the three months ended in Mar. 2024 was 円0 Mil. Daiichinkyo Co paid 円0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Daiichinkyo Co's cash flow for dividends for the three months ended in Mar. 2024 was 円61 Mil. Daiichinkyo Co received 円61 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Daiichinkyo Co's other financing for the three months ended in Mar. 2024 was 円0 Mil. Daiichinkyo Co received 円0 Mil on other financial activities.


Daiichinkyo Co Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co (TSE:4568) Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co (TSE:4568) Headlines

No Headlines